Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc. (Nasdaq: NAUT) is a development-stage life sciences company developing proteomics technology to measure proteins and their functional variants, called proteoforms. Its Nautilus Voyager platform combines instruments, consumables and software to analyze individual intact protein molecules… From the company’s description.
In fiscal 2025, Nautilus Biotechnology, Inc. reported a net loss of $59.00M. Operations used $50.70M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Nautilus Biotechnology, Inc. does
In the company’s own words
Nautilus Biotechnology, Inc. (Nasdaq: NAUT) is a development-stage life sciences company developing proteomics technology to measure proteins and their functional variants, called proteoforms. Its Nautilus Voyager platform combines instruments, consumables and software to analyze individual intact protein molecules using its Iterative Mapping method, with applications designed for broadscale proteome analysis and targeted proteoform analysis. The company’s intended customers include biopharmaceutical companies, academic institutions and research organizations; its January 2026 Early Access Program offers standardized proteomics analysis services for select customers. Nautilus operates as a single business focused on developing and commercializing this platform, rather than reporting multiple business segments. Its research collaborations include Genentech, the Michael J. Fox Foundation, Weill Cornell Medicine–Qatar and the Buck Institute for Research on Aging, and it has an agreement with the Allen Institute. The company was formed in its present structure after a 2021 business combination with ARYA Sciences Acquisition Corp III, through which Legacy Nautilus became a wholly owned subsidiary. Its website is https://www.nautilus.bio.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- SEATTLE, WA
- Fiscal year end
- December
- CIK
- 1808805
- SIC
- 3826
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Nautilus Biotechnology, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Nautilus Biotechnology, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Nautilus Biotechnology, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Nautilus Biotechnology, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Nautilus Biotechnology, Inc.'s last four quarterly filings that the numbers alone won't show?”